New antibody drug targets tough lung cancer in early trial
Disease control
Recruiting now
This Phase 2 trial tests tarlatamab, a bispecific antibody that helps immune cells attack cancer cells, in 39 patients with extensive-stage small-cell lung cancer. The goal is to see if it can delay cancer growth and improve survival. Participants will receive tarlatamab and unde…
Phase: PHASE2 • Sponsor: Asrar Alahmadi • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC